View in EDS HTML Full Text PDF Full Text

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).

Saved in:
Bibliographic Details
Title: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
Authors: Hochster HS; Rutgers Cancer Institute, New Brunswick, NJ, USA., Catalano P; ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Weitz M; ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Cohen D; Mt Sinai Hospital, New York, NY, USA., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA., Faller BA; Missouri Baptist Medical Center Heartland NCORP, St Louis, MO, USA., Kortmansky JS; Yale Cancer Center, New Haven, CT, USA., O'Hara MH; University of Pennsylvania, Philadelphia, PA, USA., Kricher SM; Northwestern University, Chicago, IL, USA., Lacy J; Yale Cancer Center, New Haven, CT, USA., Lenz HJ; Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Verma U; University of Texas, Southwestern Medical Center, Dallas, TX, USA., Benson AB; Northwestern University, Chicago, IL, USA.
Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Sep 01; Vol. 116 (9), pp. 1487-1494.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1460-2105
DOI:10.1093/jnci/djae114